Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic.
Anxiety
COVID-19
Depression
Parkinson disease
Worries
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
21
02
2021
accepted:
22
04
2021
pubmed:
6
5
2021
medline:
6
1
2022
entrez:
5
5
2021
Statut:
ppublish
Résumé
The psychological impact of the COVID-19 outbreak and lockdown on frail populations with advanced Parkinson disease (APD) and their caregivers may present with peculiar features and require specific interventions. We enrolled here 100 APD patients and 60 caregivers. Seventy-four patients were treated with device-aided therapies (DAT) and 26 with standard medical treatment (SMT). Through a telephonic interview, subjects underwent the Hospital Anxiety and Depression Scale (HADS-A; HADS-D), and an ad hoc questionnaire to explore thoughts and emotions related to the pandemic. Depression was observed in 35% of APD patients and anxiety in 39%, with a significant reduction of the latter after the lockdown (p= 0.023). We found a significant correlation between the type of therapy and the HADS-A score (p= 0.004). Patients' main worries were as follows: a possible higher risk of COVID-19 infection (25%), interruption of non-pharmacological treatments (35%), interruption of outpatient clinics (38%), PD complications related to COVID-19 (47%). Patients treated with DAT manifested worries about device-related issues and risk for caregivers' infection. The 40% of caregivers showed anxiety, while the 21.7% of them showed depression. Our study reveals a higher prevalence of anxiety and the presence of peculiar worries and needs in APD patients during the pandemic alongside psychological sequelae of their caregivers. These findings are important for neurologists and healthcare services to foster strategies for the management of psychological distress in both patients and caregivers.
Sections du résumé
BACKGROUND
BACKGROUND
The psychological impact of the COVID-19 outbreak and lockdown on frail populations with advanced Parkinson disease (APD) and their caregivers may present with peculiar features and require specific interventions.
METHODS
METHODS
We enrolled here 100 APD patients and 60 caregivers. Seventy-four patients were treated with device-aided therapies (DAT) and 26 with standard medical treatment (SMT). Through a telephonic interview, subjects underwent the Hospital Anxiety and Depression Scale (HADS-A; HADS-D), and an ad hoc questionnaire to explore thoughts and emotions related to the pandemic.
RESULTS
RESULTS
Depression was observed in 35% of APD patients and anxiety in 39%, with a significant reduction of the latter after the lockdown (p= 0.023). We found a significant correlation between the type of therapy and the HADS-A score (p= 0.004). Patients' main worries were as follows: a possible higher risk of COVID-19 infection (25%), interruption of non-pharmacological treatments (35%), interruption of outpatient clinics (38%), PD complications related to COVID-19 (47%). Patients treated with DAT manifested worries about device-related issues and risk for caregivers' infection. The 40% of caregivers showed anxiety, while the 21.7% of them showed depression.
CONCLUSION
CONCLUSIONS
Our study reveals a higher prevalence of anxiety and the presence of peculiar worries and needs in APD patients during the pandemic alongside psychological sequelae of their caregivers. These findings are important for neurologists and healthcare services to foster strategies for the management of psychological distress in both patients and caregivers.
Identifiants
pubmed: 33948763
doi: 10.1007/s10072-021-05286-z
pii: 10.1007/s10072-021-05286-z
pmc: PMC8096160
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-348Informations de copyright
© 2021. The Author(s).
Références
World Health Organization (2020) Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ . (accessed: May 20th 2020)
Brooks S, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ (2020) The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 395(10227):912–920. https://doi.org/10.1016/S0140-6736(20)30460-8
doi: 10.1016/S0140-6736(20)30460-8
pubmed: 32112714
pmcid: 7158942
Weintraub D, Mamikonyan E (2019) The neuropsychiatry of Parkinson disease: a perfect storm. Am J Geriatr Psychiatry 27(9):998–1018. https://doi.org/10.1016/j.jagp.2019.03.002
doi: 10.1016/j.jagp.2019.03.002
pubmed: 31006550
pmcid: 7015280
Oppo V, Serra G, Fenu G, Murgia D, Ricciardi L, Melis M, Morgante F, Cossu G (2020) Parkinson’s disease symptoms have a distinct impact on caregivers’ and patients’ stress: a study assessing the consequences of the COVID-19 lockdown. Mov Disord Clin Pract 7(7):865–867
doi: 10.1002/mdc3.13030
Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, Ashourizadeh H (2020) Incidence of anxiety in Parkinson’s Disease during coronavirus disease (COVID-19) pandemic. Mov Disord 35(7):1095–1096. https://doi.org/10.1002/mds.28116
doi: 10.1002/mds.28116
pubmed: 32395849
Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E (2020) Mental health, physical activity, and quality of life in Parkinson’s disease during COVID-19 pandemic. Mov Disord 35(7):1097–1099. https://doi.org/10.1002/mds.28134
doi: 10.1002/mds.28134
pubmed: 32428342
Artusi CA, Romagnolo A, Imbalzano G, Marchet A, Zibetti M, Rizzone MG, Lopiano L (2020) COVID-19 in Parkinson’s disease: report on prevalence and outcome. Parkinsonism Relat Disord 80:7–9. https://doi.org/10.1016/j.parkreldis.2020.09.008
doi: 10.1016/j.parkreldis.2020.09.008
pubmed: 32920322
pmcid: 7474816
Schirinzi T, Cerroni R, Di Lazzaro G et al (2020) Self-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy. Neurol Sci 41(6):1373–1375. https://doi.org/10.1007/s10072-020-04442
doi: 10.1007/s10072-020-04442
pubmed: 32363506
Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34(12):2063–2073. https://doi.org/10.1080/03007995.2018.1502165
doi: 10.1080/03007995.2018.1502165
pubmed: 30016901
Ossig C, Reichmann H (2013) Treatment of Parkinson’s disease in the advanced stage. J Neural Transm 120(4):523–529. https://doi.org/10.1007/s00702-013-1008-y
doi: 10.1007/s00702-013-1008-y
pubmed: 23474822
Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67(6):361–370
doi: 10.1111/j.1600-0447.1983.tb09716.x
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
doi: 10.1016/0022-3956(75)90026-6
Bloem BR, de Vries NM, Ebersbach G (2015) Nonpharmacological treatments for patients with Parkinson's disease. Mov Disord 30(11):1504–1520. https://doi.org/10.1002/mds.26363s
doi: 10.1002/mds.26363s
pubmed: 26274930
Xu X, Fu Z, Le W (2019) Exercise and Parkinson’s disease. Int Rev Neurobiol 147:45–74. https://doi.org/10.1016/bs.irn.2019.06.003
doi: 10.1016/bs.irn.2019.06.003
pubmed: 31607362
Miele G, Straccia G, Moccia M, Leocani L, Tedeschi G, Bonavita S, Lavorgna L (2020) Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology, 2020. Telemedicine in Parkinson’s disease: how to ensure patient needs and continuity of care at the time of COVID-19 Pandemic. Telemed J E Health 26(12):1533–1536. https://doi.org/10.1089/tmj.2020.0184
doi: 10.1089/tmj.2020.0184
pubmed: 32667839
Krüger R, Hilker R, Winkler C, Lorrain M, Hahne M, Redecker C (2016) Advanced stages of PD: interventional therapies and related patient-centered care. J Neural Transm 123(1):31–43. https://doi.org/10.1007/s00702-015-1418-0
doi: 10.1007/s00702-015-1418-0
pubmed: 26138439
Xia Y, Kou L, Zhang G, Han C, Hu J, Wan F, Yin S, Sun Y, Wu J, Li Y, Zhang Z, Huang J, Xiong N, Wang T (2020) Investigation on sleep and mental health of patients with Parkinson’s disease during the coronavirus disease 2019 pandemic. Sleep Med 75:428–433. https://doi.org/10.1016/j.sleep.2020.09.011
doi: 10.1016/j.sleep.2020.09.011
pubmed: 32980664
pmcid: 7481072
van der Heide A, Meinders MJ, Bloem BR, Helmich RC (2020) The impact of the COVID-19 pandemic on psychological distress, physical activity, and symptom severity in Parkinson’s disease. J Parkinsons Dis 10(4):1355–1364. https://doi.org/10.3233/JPD-202251
doi: 10.3233/JPD-202251
pubmed: 32925108
pmcid: 7683090
Del Prete E, Francesconi A, Palermo G, Mazzucchi S, Frosini D, Morganti R, Coleschi P, Raglione LM, Vanni P, Ramat S, Novelli A, Napolitano A, Battisti C, Giuntini M, Rossi C, Menichetti C, Ulivelli M, De Franco V, Rossi S, Bonuccelli U, Ceravolo R, Tuscany Parkinson COVID-19 Participants (2021) Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region. J Neurol 268(4):1179–1187. https://doi.org/10.1007/s00415-020-10002-6
doi: 10.1007/s00415-020-10002-6
pubmed: 32880722